Detalles de la búsqueda
1.
Buparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): a randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet Oncol
; 19(1): 87-100, 2018 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-29223745
2.
Effect of esomeprazole, a proton pump inhibitor on the pharmacokinetics of sonidegib in healthy volunteers.
Br J Clin Pharmacol
; 82(4): 1022-9, 2016 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-27277189
3.
The 12-month analysis from Basal Cell Carcinoma Outcomes with LDE225 Treatment (BOLT): A phase II, randomized, double-blind study of sonidegib in patients with advanced basal cell carcinoma.
J Am Acad Dermatol
; 75(1): 113-125.e5, 2016 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-27067394
4.
Exposure-QT analysis for sonidegib (LDE225), an oral inhibitor of the hedgehog signaling pathway, for measures of the QT prolongation potential in healthy subjects and in patients with advanced solid tumors.
Eur J Clin Pharmacol
; 72(12): 1427-1432, 2016 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-27663457
5.
Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): a multicentre, randomised, double-blind phase 2 trial.
Lancet Oncol
; 16(6): 716-28, 2015 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-25981810
6.
Effect of everolimus on survival in advanced hepatocellular carcinoma after failure of sorafenib: the EVOLVE-1 randomized clinical trial.
JAMA
; 312(1): 57-67, 2014 Jul 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-25058218
7.
Phase I study investigating everolimus combined with sorafenib in patients with advanced hepatocellular carcinoma.
J Hepatol
; 59(6): 1271-7, 2013 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-23928403
8.
Patritumab Deruxtecan (HER3-DXd), a Human Epidermal Growth Factor Receptor 3-Directed Antibody-Drug Conjugate, in Patients With Previously Treated Human Epidermal Growth Factor Receptor 3-Expressing Metastatic Breast Cancer: A Multicenter, Phase I/II Trial.
J Clin Oncol
; 41(36): 5550-5560, 2023 Dec 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-37801674
9.
HERTHENA-Lung01, a Phase II Trial of Patritumab Deruxtecan (HER3-DXd) in Epidermal Growth Factor Receptor-Mutated Non-Small-Cell Lung Cancer After Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and Platinum-Based Chemotherapy.
J Clin Oncol
; 41(35): 5363-5375, 2023 Dec 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-37689979
10.
A Phase II Randomized Study of Neoadjuvant Letrozole Plus Alpelisib for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer (NEO-ORB).
Clin Cancer Res
; 25(10): 2975-2987, 2019 05 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-30723140
11.
A Phase Ib, open-label, dose-finding study of alpelisib in combination with paclitaxel in patients with advanced solid tumors.
Oncotarget
; 9(60): 31709-31718, 2018 Aug 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-30167089
12.
Effects of Mild to Severe Hepatic Impairment on the Pharmacokinetics of Sonidegib: A Multicenter, Open-Label, Parallel-Group Study.
Clin Pharmacokinet
; 57(3): 345-354, 2018 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-28577129
13.
Molecular Alterations and Buparlisib Efficacy in Patients with Squamous Cell Carcinoma of the Head and Neck: Biomarker Analysis from BERIL-1.
Clin Cancer Res
; 24(11): 2505-2516, 2018 06 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-29490986
14.
Buparlisib plus fulvestrant versus placebo plus fulvestrant for postmenopausal, hormone receptor-positive, human epidermal growth factor receptor 2-negative, advanced breast cancer: Overall survival results from BELLE-2.
Eur J Cancer
; 103: 147-154, 2018 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-30241001
15.
A Matching-Adjusted Indirect Comparison of Sonidegib and Vismodegib in Advanced Basal Cell Carcinoma.
J Skin Cancer
; 2017: 6121760, 2017.
Artículo
en Inglés
| MEDLINE | ID: mdl-28607774
16.
Exposure-Response Analysis of Sonidegib (LDE225), an Oral Inhibitor of the Hedgehog Signaling Pathway, for Effectiveness and Safety in Patients With Advanced Solid Tumors.
J Clin Pharmacol
; 56(11): 1406-1415, 2016 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-27095306
17.
Population pharmacokinetics of sonidegib (LDE225), an oral inhibitor of hedgehog pathway signaling, in healthy subjects and in patients with advanced solid tumors.
Cancer Chemother Pharmacol
; 77(4): 745-55, 2016 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-26898300
18.
[Total body irradiation: techniques and main indications]. / Irradiation corporelle totale: techniques et indications.
Tunis Med
; 83(10): 581-5, 2005 Oct.
Artículo
en Francés
| MEDLINE | ID: mdl-16370205
19.
Loss of Tuberous Sclerosis Complex 2 (TSC2) Is Frequent in Hepatocellular Carcinoma and Predicts Response to mTORC1 Inhibitor Everolimus.
Mol Cancer Ther
; 14(5): 1224-35, 2015 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-25724664
20.
Radio-induced malignancies of the scalp about 98 patients with 150 lesions and literature review.
Cancer Radiother
; 8(2): 81-7, 2004 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-15063875